Simona Heidempergher

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy.

Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy.

Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.